Clinical Trials Sponsored by Dana Horakova

Total 2021 results

Dana-Farber Cancer Institute

Recruiting

Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial

Pancreatic Cancer

United States
Dana-Farber Cancer Institute

Recruiting

Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial (RESTART)

Graft Vs Host Disease | Acute-graft-versus-host Disease | Chronic Graft-versus-host-disease

United States
Dana-Farber Cancer Institute

Recruiting

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

Ovarian Cancer | Endometrial Cancer | Ovarian Carcinoma | Ovarian Cancer Stage IV | Ovarian Cancer Stage III | Ovarian Cancer Stage 3 | Endometrial Cancer Stage

United States
Dana-Farber Cancer Institute

Recruiting

A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma

Cutaneous T Cell Lymphoma | Peripheral T Cell Lymphoma

United States
Dana-Farber Cancer Institute

Recruiting

Hereditary Risk Factors for Thyroid Cancer

Thyroid Cancer

United States
Dana-Farber Cancer Institute

Recruiting

Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture

Bone Mineral Density | Childhood Cancer Survivors

United States
Dana-Farber Cancer Institute

Active, not recruiting

INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy

Breast Cancer | Breast Carcinoma | Breast Cancer Female

United States
Dana-Farber Cancer Institute

Active, not recruiting

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Chronic Myelomonocytic Leukemia | Myeloproliferative Neoplasms

United States
Dana-Farber Cancer Institute

Active, not recruiting

GVAX Plus Checkpoint Blockade in Neuroblastoma

Neuroblastoma | Pediatric Solid Tumor

United States
Dana-Farber Cancer Institute

Active, not recruiting

Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome

Recurrent, Refractory, or High Risk Leukemias | Matched Targeted Therapy

United States
Dana-Farber Cancer Institute

Completed

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Solid Tumors | KRAS Mutant Non-Small Cell Lung Cancer

United States
Dana-Farber Cancer Institute

Completed

Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy

Breast Cancer

United States
Dana-Farber Cancer Institute

Completed

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Carcinoid Tumor | Pancreatic Neuroendocrine Tumor

United States
Dana-Farber Cancer Institute

Active, not recruiting

Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy

Pediatric Cancer | Skin Inflammation | CNS Tumor, Childhood

United States
Dana-Farber Cancer Institute

Active, not recruiting

PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions

Breast Cancer

United States
Dana-Farber Cancer Institute

Active, not recruiting

Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders

Multiple Myeloma | Lymphoblastic Lymphoma | Waldenstrom's Macroglobulinemia | Smoldering Multiple Myeloma

United States
Dana-Farber Cancer Institute

Completed

Ear Acupuncture During Chemotherapy Infusion for Breast Cancer, a Feasibility Study

Breast Cancer

United States
Dana-Farber Cancer Institute

Terminated

Axillary Lymph Node Tattoo Marking Study

Breast Cancer | Lymph Node Metastases

United States
Dana-Farber Cancer Institute

Active, not recruiting

Feasibility of Fasting & Exercise in Pts With HR+ MBC

Breast Cancer | Metastatic Breast Cancer

United States
Dana-Farber Cancer Institute

Completed

Gut Decontamination In Pediatric Allogeneic Hematopoietic

Hematopoietic Stem Cell Transplantation (HSCT) | Acute GVH Disease

United States
Dana-Farber Cancer Institute

Withdrawn

Implantable Microdevice for TNBC - Pilot Study

Breast Cancer | Breast Neoplasms | Breast Carcinoma | Triple Negative Breast Cancer | Breast Cancer Stage II | Breast Cancer Stage III | Early Stage Triple-Negative Breast Carcinoma

United States
Dana-Farber Cancer Institute

Completed

Routine Evaluation of the Social Determinants of Health in Oncology: User-centered Resource Coordination and Engagement (RESOURCE)

Breast Cancer | Lung Cancer | Gastrointestinal Cancer

United States
Dana-Farber Cancer Institute

Completed

Step Into Support for Endurance and Strength (SISTERS) (SISTERS)

Gynecologic Cancer

United States
Dana-Farber Cancer Institute

Completed

Image-Guided Gynecologic Brachytherapy (AMIGO)

Cervical Cancer | Vaginal Cancer | Uterine Cancer | Carcinoma of the Vulva

United States
Dana-Farber Cancer Institute

Completed

Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy

Early Stage Breast Cancer | Breast Cancer Stage I | Breast Cancer Stage II

United States
Dana-Farber Cancer Institute

Completed

TIPOPS (Telemedicine vs In Person Oncology Patient Surveillance)

Breast Cancer | Prostate Cancer | Patient Engagement | Patient Satisfaction | Patient Preference

United States
Dana-Farber Cancer Institute

Completed

Mindfulness-Music Intervention for Adolescents and Young Adults With Cancer (MAYA)

Stress | Anxiety | Oncology

United States
Dana-Farber Cancer Institute

Completed

Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation

Other Cancer

United States
Dana-Farber Cancer Institute

Completed

Videos for Advance Care Planning in Young Adults

Advanced Cancer

United States
Dana-Farber Cancer Institute

Completed

Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for Pain

Cancer

United States
Dana-Farber Cancer Institute

Completed

Intravenous Magnesium in Patients Receiving Cisplatin

Mesothelioma

United States
Dana-Farber Cancer Institute

Completed

Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy

Prostate Cancer

United States
Dana-Farber Cancer Institute

Completed

Cisplatin + RT for Triple Negative Breast Cancer

Breast Cancer

United States
Dana-Farber Cancer Institute

Completed

Pembrolizumab +/- Bevacizumab for Recurrent GBM

Glioblastoma

United States
Dana-Farber Cancer Institute

Terminated

The Value of Advanced MR Imaging in Gynecological Tumors and Benign Uterine Fibroids

Gynecologic Tumor

United States
Dana-Farber Cancer Institute

Completed

The GI Binder: A Psychoeducational Intervention for Gastrointestinal Cancer Patients

Gastro Intestinal Cancer

United States
Dana-Farber Cancer Institute

Completed

Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD

Chronic Versus Graft Host Disease

United States
Dana-Farber Cancer Institute

Completed

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Dana-Farber Cancer Institute

Completed

Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning

Prostate Cancer | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage III

United States
Dana-Farber Cancer Institute

Completed

BKM120 For Triple Negative Breast Cancer

Breast Cancer

United States
Dana-Farber Cancer Institute

Completed

Exercise and Metformin in Colorectal and Breast Cancer Survivors

Breast Cancer | Colorectal Cancer

United States
Dana-Farber Cancer Institute

Completed

Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Dana-Farber Cancer Institute

Completed

Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant

Graft Versus Host Disease

United States
Dana-Farber Cancer Institute

Completed

Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

Lymphoma | Leukemia | Myelodysplastic Syndrome

United States
Dana-Farber Cancer Institute

Terminated

Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma

Multiple Myeloma | Thrombocytopenia

United States
Dana-Farber Cancer Institute

Completed

Cabozantinib for Metastatic Triple Negative BrCa

Breast Cancer

United States
Dana-Farber Cancer Institute

Terminated

Simvastatin in Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Dana-Farber Cancer Institute

Terminated

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

Non-Small Cell Lung Cancer, Head and Neck Cancer

United States
Dana-Farber Cancer Institute

Withdrawn

Tivozanib + Gemcitabine in Metastatic RCC

Renal Cell Carcinoma

United States
Dana-Farber Cancer Institute

Completed

Observational Study of Iron Overload in Stem Cell Transplantation

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States

Clinical Trials Sponsored by Dana Horakova

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations